RGC (Regencell Bioscience Holdings) Current Accrued Expense : $0.13 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Current Accrued Expense?

Regencell Bioscience Holdings's Current Accrued Expense for the quarter that ended in Jun. 2024 was $0.13 Mil.

Regencell Bioscience Holdings's quarterly Current Accrued Expense declined from Jun. 2023 ($0.16 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Jun. 2024 ($0.13 Mil).

Regencell Bioscience Holdings's annual Current Accrued Expense increased from Jun. 2022 ($0.15 Mil) to Jun. 2023 ($0.16 Mil) but then declined from Jun. 2023 ($0.16 Mil) to Jun. 2024 ($0.13 Mil).

Regencell Bioscience Holdings Current Accrued Expense Historical Data

The historical data trend for Regencell Bioscience Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Current Accrued Expense Chart

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Current Accrued Expense

Get a 7-Day Free Trial

0.10

0.57

0.15

0.16

0.13

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Current Accrued Expense	Get a 7-Day Free Trial						0.15	-	0.16	-	0.13

Regencell Bioscience Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Regencell Bioscience Holdings Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.